ValiRx Subsidiary Strikes US Co-Marketing Deal
Company Announcements

ValiRx Subsidiary Strikes US Co-Marketing Deal

ValiRx plc (GB:VAL) has released an update.

ValiRx Plc’s subsidiary Inaphaea BioLabs has entered into a co-marketing agreement with U.S. firm Spanios LLC to enhance drug screening and development services. The collaboration combines Inaphaea’s high throughput drug screening using Patient Derived Cells with Spanios’s Patient Derived Tumoroids platform, aiming to accelerate the drug development process. The initial agreement spans 12 months, with possibilities for extension, marking Inaphaea’s first co-marketing move in the U.S.

For further insights into GB:VAL stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks UK Auto-Generated NewsdeskValiRx Extends Exclusivity Agreement with TheoremRx
TipRanks UK Auto-Generated NewsdeskValiRx plc Announces Board Changes Amid Strategic Focus
TipRanks UK Auto-Generated NewsdeskValiRx plc to Reveal Future Strategies in CEO Webinar
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App